With your risk of dementia post stroke, you'll want this test so your competent? doctor can give you EXACT PREVENTION PROCOLS! You need to ask for those protocols now because you don't want your doctor scrambling to put them together when you need them.
With your extra risk of dementia post stroke; DOES YOUR DOCTOR HAVE EXACT DEMENTIA PREVENTION PROTOCOLS? NO? So, your doctor is incompetent?
1. A documented 33% dementia chance post-stroke from an Australian study? May 2012.
2. Then this study came out and seems to have a range from 17-66%. December 2013.`
3. A 20% chance in this research. July 2013.
4. Dementia Risk Doubled in Patients Following Stroke September 2018
Midlife blood test may reveal Alzheimer’s disease risk in advance
A simple blood test for platelet activity at middle age could one day help identify people at risk for Alzheimer's disease decades ahead of time, allowing for possible preventive therapy.
The blood-clotting process in vascular dysfunction is linked to key markers of Alzheimer's as early as midlife, a study co-led by researchers at The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, and the New York University Grossman School of Medicine shows.
Vascular dysfunction refers to a condition in which blood vessels do
not function properly, with a number of causes from abnormal blood clots
to atherosclerosis, inflammation,
diabetes, high blood pressure, smoking and age. It generally is
recognized as contributing to the risk of Alzheimer's and related
dementias, but the underlying mechanisms have been unclear.
The team led by the Biggs Institute and NYU identifies one of those
mechanisms – platelet aggregation, the process by which platelets or
small blood cells form a clot.
Specifically, the scientists link the platelet aggregation response in
the blood to positron emission tomography (PET) and magnetic resonance
imaging (MRI) brain markers of Alzheimer's disease risk in middle-aged
people. The breakthrough could have broad implications for both
diagnosing the disease and identifying new therapies at an early stage
of aging, many years before Alzheimer's symptoms are evident.
"We believe that since platelets are easy to obtain in the blood, they
could eventually become part of midlife screening to identify people at
risk and apply preventive interventions targeting platelet-related
inflammation," said Sudha Seshadri, MD, professor of neurology, founding
director of the Biggs Institute and senior author of the study,
"Association of Platelet Aggregation With Markers of Alzheimer Disease
Pathology in Middle-Aged Participants of the Framingham Heart Study,"
published Nov. 4 in the journal Neurology.
Vascular component of Alzheimer's
A vascular component of Alzheimer's disease has been discussed since the 1960s, but a key limitation in defining it has been its frequent overlap with cerebrovascular disease, the study notes.
Up to 75% of patients diagnosed with Alzheimer's also show vascular
pathology, and 25% of patients with vascular dementia over the age of 75
show amyloid pathology, an indicator of increased risk of Alzheimer's.
The new study analyzed 382 dementia-free participants with an average
age of 56 enrolled in the Framingham Heart Study, a long-term and
ongoing community-based observational study of residents in Framingham,
Massachusetts, dating to 1948.
Researchers previously had identified that among middle-aged Framingham
participants free of anti-platelet therapy, platelet aggregation was
independently associated with the risk of incident dementia during a
20-year follow-up, adjusting for potential demographic and clinical
variables.
So scientists this time sought an association between platelet aggregation and actual Alzheimer's biomarkers at midlife.
The Framingham study has one of the largest repositories of platelet
aggregation data and Alzheimer's biomarkers available. And PET imaging, a
nuclear medicine technique that uses radioactive tracers to create
detailed images of organs and tissues in the body, was acquired in
conjunction with MRI from a large subsample of middle-aged participants
in Framingham's third-generation cohort.
The research team measured platelet aggregation in the Framingham
participants using a leading laboratory test for diagnosing platelet
dysfunction called light transmission aggregometry (LTA). Then, they
evaluated associations between platelet aggregation and amyloid and tau –
the hallmark proteins of Alzheimer's – on PET and MRI brain scans.
The results indicated a positive link: People whose platelets clump
together more strongly also tend to have higher levels of amyloid and
tau proteins in the brain, which are hallmarks of Alzheimer's disease.
However, this link isn't the same across everyone.
"The relationship shows up in people whose platelets are at the lowest
end of the activity scale with the experiments that were used," said
Alexa Beiser, professor of biostatistics at the Boston University School
of Public Health who has been working with Framingham data for decades
and played a fundamental role in the statistical analysis of the study.
"In that group, stronger platelet clumping goes hand-in-hand with more
amyloid and tau on brain scans. For people with higher platelet
activity, the relationship is less clear.",
Still, the scientists concluded that circulating platelets in the blood
may offer early clues to Alzheimer's risk – perhaps decades before
symptoms appear – with the data suggesting that certain features of the
platelets in midlife may be tied to early brain changes linked to the
disease.
Our study underscores the need to further clarify the role of platelet-mediated inflammation in brain aging disorders and Alzheimer's disease and related dementias in particular. This may open new opportunities for interventions many years before symptoms are evident. We believe platelets may represent a unique bridge between vascular dysfunction and brain inflammation."
Jaime Ramos-Cejudo, PhD, assistant professor of psychiatry and neurology at NYU, and first author of the study
SLAS EU - Highlights from 2022 eBook Check out the key interviews from SLAS Europe 2023 Download the latest editionRamos-Cejudo
is principal investigator of a new five-year, $8 million grant award
from the National Institute on Aging of the National Institutes of
Health to further study how peripheral inflammation, and platelet
activity in particular, contribute to brain aging and the progression of
Alzheimer's and related dementias.
Mohamad Habes, PhD, director of the neuroimaging core at the Biggs
Institute, and Beiser are sub-award principal investigators for the
grant.
Other authors of the just-published study additionally are with
Harvard Medical School, University of California-Davis and the
Hemostasis and Platelet Biology Lab at the National Heart, Lung, and
Blood Institute of Framingham, Massachusetts.
The Biggs Institute soon will be housed in the new $100 million Center
for Brain Health at UT Health San Antonio, set to open in December, and
with a ribbon-cutting this Wednesday, Nov. 12. The 103,000-square-foot
center is designed to provide a comprehensive and hopeful experience for
individuals facing neurological diseases, while advancing the science
behind diagnosis and treatment.
Ramos-Cejudo, J., et al. (2025). Association of Platelet Aggregation With Markers of Alzheimer Disease Pathology in Middle-Aged Participants of the Framingham Heart Study. Neurology. doi: 10.1212/wnl.0000000000214314. https://www.neurology.org/doi/10.1212/WNL.0000000000214314
No comments:
Post a Comment